Gene therapy legislation in The Netherlands

✍ Scribed by D. A. Bleijs; I. T. W. C. Haenen; J. E. N. Bergmans

• Publisher: John Wiley and Sons
• Year: 2007
• Tongue: English
• Weight: 105 KB
• Volume: 9
• Category: Article
• ISSN: 1099-498X
• DOI: 10.1002/jgm.1095

✦ Synopsis

Abstract

Several regulatory organisations are involved in the assessment of clinical gene therapy trials involving genetically modified organisms (GMOs) in The Netherlands. Medical, ethical and scientific aspects are, for instance, evaluated by the Central Committee on Research Involving Human Subjects (CCMO). The Ministry of Housing, Spatial Planning and the Environment (VROM) is the competent authority for the environmental risk assessment according to the deliberate release Directive 2001/18/EC. A Gene Therapy Office has been established in order to streamline the different national review processes and to enable the official procedures to be completed as quickly as possible. Although the Gene Therapy Office improved the application process at the national level, there is a difference of opinion between the EU member states with respect to the EU Directive according to which gene therapy trials are assessed, that urges for harmonisation. This review summarises the gene therapy legislation in The Netherlands and in particular The Netherlands rationale to follow Directive 2001/18/EC for the environmental risk assessment. Copyright © 2007 John Wiley & Sons, Ltd.